“Assessing Clinical Progression Measures in Alzheimer’s Disease Trials: A Systematic Review and Meta-Analysis.”

Jonathan McLaughlin, et al. – University College London.

This meta-analysis examined 25 AD clinical trials to determine the ideal metrics for gauging treatment success. Looking at which tests showed the greatest changes in the placebo groups – thereby providing the greatest opportunity for treatments to demonstrate improvement – the authors found that functional assessments performed better than purely cognitive ones, with tests blending both performing best. Most trials included tests of all 3 of these types, allowing for head-to-head comparisons of how different ones perform in the same cohort. This reinforces the need to assess patients and subjects from a variety of angles.